How to keep muscle and bone while losing weight on semaglutide or tirzepatide
A new review says GLP-1 weight loss mostly burns fat, but protein, resistance training and smart monitoring protect muscle, bone and nutrition.
Summary
GLP-1 drugs like semaglutide and tirzepatide produce large weight loss, so attention is shifting from how much weight is lost to what kind of tissue is lost. This review concludes that these drugs mostly reduce fat, including harmful visceral fat, with smaller but consistent drops in lean mass. A drop in scanner-measured lean mass is not the same as losing working muscle or strength. The authors recommend a food-first approach with adequate protein, structured resistance exercise, management of nausea and constipation, and checks for nutrient shortfalls. Protein shakes or complete meal replacements can help when eating is low. Creatine, leucine, HMB, fiber, probiotics and omega-3s are optional extras with thin evidence. Better tracking of muscle, function and bone is needed.
Detailed Summary
GLP-1-based obesity drugs have changed treatment. Once-weekly semaglutide 2.4 mg produced about 15% weight loss at 68 weeks, and tirzepatide reached 15 to 21% across phase 3 trials. As efficacy has increased, the clinical question has moved from kilograms lost to the quality and functional consequences of that loss. This review asks whether the body composition changes seen on these drugs represent clinically meaningful muscle loss, and which nutrition, supplementation, exercise and monitoring strategies may help preserve lean mass, function, bone and nutritional adequacy.
The authors, from the University of Split School of Medicine and University Hospital of Split in Croatia, wrote a comprehensive narrative review rather than a systematic one. They used focused searches of PubMed, publisher-hosted journal platforms and reference lists of key primary studies and recent evidence syntheses through March and May 2026. Evidence was organized around body composition, muscle quality and function, protein and micronutrient adequacy, exercise, supplementation, bioelectrical impedance analysis (BIA), imaging and emerging biomarkers.
A central argument concerns terminology. DXA-derived lean mass and BIA-derived fat-free mass are not equivalent to skeletal muscle. A decline in lean tissue does not necessarily mean impaired strength or physical performance.
On results, semaglutide and tirzepatide preferentially reduce fat mass, including visceral and ectopic fat. They also produce smaller but consistent reductions in lean mass or lean soft tissue.
The most defensible supportive care model combines food-first nutritional counseling, adequate protein intake, structured resistance exercise, management of gastrointestinal side effects and risk-based monitoring for micronutrient inadequacy. Protein supplements and nutritionally complete meal replacements may help when intake is insufficient. Creatine, essential amino acids or leucine, HMB, fiber, probiotics, omega-3 fatty acids and multi-ingredient products remain adjunctive options supported mainly by indirect or phenotype-specific evidence.
The main caveat is that much of the supportive-care evidence is indirect. As a narrative review, it does not pool data. The authors call for future GLP-1 trials and clinical care to move beyond body weight and total lean mass toward integrated assessment of muscle quantity, muscle quality, function, bone and nutritional adequacy. They also call for standardized BIA-based clinical monitoring where advanced imaging is not feasible.
Key Findings
- Semaglutide 2.4 mg produced about 15% mean weight loss at 68 weeks, and tirzepatide produced 15 to 21% across phase 3 obesity trials
- Semaglutide and tirzepatide preferentially reduce fat mass, including visceral and ectopic fat, with smaller but consistent lean mass reductions
- DXA lean mass and BIA fat-free mass are not equivalent to skeletal muscle, and lean tissue loss does not necessarily mean impaired strength or performance
- Best-supported care model: food-first counseling, adequate protein, structured resistance exercise, GI side-effect management and risk-based micronutrient monitoring
- Protein supplements and complete meal replacements are useful when intake is insufficient, while creatine, leucine/EAA, HMB, fiber, probiotics, omega-3s and multi-ingredient products rest mainly on indirect or phenotype-specific evidence
- The authors call for integrated assessment of muscle quantity, quality, function, bone and nutrition, with standardized BIA monitoring where advanced imaging is not feasible
Methodology
This is a comprehensive narrative review, not a systematic review or meta-analysis. The authors used focused searches of PubMed, publisher-hosted journal platforms and reference lists of key primary studies and recent evidence syntheses through March and May 2026. Evidence was organized thematically: body composition, muscle quality and function, protein and micronutrient adequacy, exercise, supplementation, BIA, imaging and emerging biomarkers. No pooled effect sizes were calculated.
Study Limitations
As a narrative review, it has no formal risk-of-bias assessment or pooled analysis, and many supportive-care recommendations are extrapolated from non-GLP-1, older-adult or sarcopenia studies. Few GLP-1 trials were designed around lean mass, strength or bone outcomes, so direct evidence for supplements is sparse. The authors report no external funding.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: